Bio-Rad Laboratories, Inc. $BIO Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 46,332.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 74,756 shares of the medical research company’s stock after purchasing an additional 74,595 shares during the quarter. Northwestern Mutual Wealth Management Co. owned about 0.28% of Bio-Rad Laboratories worth $22,650,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Sector Gamma AS raised its stake in Bio-Rad Laboratories by 28.0% in the 3rd quarter. Sector Gamma AS now owns 22,827 shares of the medical research company’s stock valued at $6,400,000 after purchasing an additional 4,998 shares during the last quarter. Natixis Advisors LLC raised its stake in Bio-Rad Laboratories by 67.1% in the 3rd quarter. Natixis Advisors LLC now owns 65,069 shares of the medical research company’s stock valued at $18,245,000 after purchasing an additional 26,119 shares during the last quarter. Mangrove Partners IM LLC acquired a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $35,568,000. Gotham Asset Management LLC raised its stake in Bio-Rad Laboratories by 41.8% in the 3rd quarter. Gotham Asset Management LLC now owns 124,626 shares of the medical research company’s stock valued at $34,944,000 after purchasing an additional 36,763 shares during the last quarter. Finally, TD Asset Management Inc raised its stake in Bio-Rad Laboratories by 461.0% in the 3rd quarter. TD Asset Management Inc now owns 8,988 shares of the medical research company’s stock valued at $2,520,000 after purchasing an additional 7,386 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Down 0.4%

BIO opened at $280.56 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37. The stock has a market capitalization of $7.51 billion, a price-to-earnings ratio of 46.22 and a beta of 1.06. The business has a 50-day moving average of $273.53 and a two-hundred day moving average of $292.69. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). The business had revenue of $592.10 million during the quarter, compared to analysts’ expectations of $589.91 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.54 EPS. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BIO shares. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their target price for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada began coverage on shares of Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 target price for the company. Finally, Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $303.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.